Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion-dependent patients with β thalassaemia: Significant association between low cardiac T2* < 10 ms and cardiac events

Internal Medicine Journal

Volumn 40, Issue 6, 2010, Pages 419-426

  Patton, N ^a   Brown, G ^b   Leung, M ^c   Bavishi, K ^a   Taylor, J ^b   Lloyd, J ^a   Lee, S H ^a   Tay, L ^a   Worthley, S ^c  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

thalassaemia; Iron chelation; Iron overload; Magnetic resonance imaging

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME IMMUNOASSAY; FEMALE; FERRITIN BLOOD LEVEL; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART WEIGHT; HEMOSIDEROSIS; HUMAN; IRON OVERLOAD; KAPLAN MEIER METHOD; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; ARRHYTHMIAS, CARDIAC; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TIME FACTORS;

EID: 77953851712     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01981.x     Document Type: Article

References (36)

1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 4th edn.
2. Modell B, Berdoukas V. The Clinical Approach to Thalassaemia.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 89 : 1187 1193.
4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 761.
5. *) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001 22 : 2171 2179.
6. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 3462.
7. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006 107 : 3436 3441.
8. Wood J. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007 14 : 183 190.
9. St. Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005 105 : 855 861. (Pubitemid 40070775)
10. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded {beta}-thalassemia/HbE patients treated with an oral chelator. Blood 2004 104 : 1504 1510.
11. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006 8 : 543 547.
12. * in patients with cardiac failure secondary to iron overload. ASH Annu Meeting Abstracts 2005 106 : 3838.
13. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007 115 : 1876 1884.
14. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 : 3738 3744.
15. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002 360 : 516 520.
16. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B et al. Interscanner reproducibility of cardiovascular magnetic resonance in the early diagnosis of myocardial iron overload. J Magn Reson Imaging 2003 18 : 616 620. (Pubitemid 37345172)
17. * relaxometry in secondary haemochromatosis: impacts of technical variations. Proceedings of the International Society for Magnetic Resonance in Medicine 7-13 May; Miami Beach, FL, USA 2005 p. 1668.
18. * technique for the quantification of tissue iron. Haematologica 2006 91 : 1388 1391.
19. *. Eur J Haematol 2006 76 : 183 192.
20. * technique for the quantification of tissue iron. Haematologica 2006 91 : 1388 1391.
21. * cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003 18 : 33 9.
22. Wood J. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004 103 : 1934 1936.
23. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging 2007 25 : 1147 1151.
24. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004 104 : 263 269.
25. Tanner M, Galanello R, Dessi C, Smith G, Westwood M, Agus A et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008 10 : 12.
26. Piga A. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003 88 : 489 496.
27. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003 70 : 398 403.
28. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006 107 : 3733 3737.
29. * cardiovascular magnetic resonance. Br J Haematol 2004 127 : 348 355.
30. Wood J. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. J Lab Clin Med 2006 148 : 272 280.
31. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005 106 : 3242 3250.
32. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006 108 : 3195 3203.
33. * in transfusion dependent anemias receiving ICL670 (deferasirox). ASH Annu Meeting Abstracts 2005 106 : 3600.
34. * (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001 22 : 2171 2179.
35. * estimation techniques in iron overload disease: relationship with left ventricular function. J Cardiovasc Magn Reson 2008 10 (Suppl 1 A332.
36. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999 8 : 135 160.